Filtered By:
Drug: Tysabri

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 23 results found since Jan 2013.

Immune Responses and Anti-inflammatory Strategies in a Clinically Relevant Model of Thromboembolic Ischemic Stroke with Reperfusion
AbstractThe poor clinical relevance of experimental models of stroke contributes to the translational failure between preclinical and clinical studies testing anti-inflammatory molecules for ischemic stroke. Here, we (i) describe the time course of inflammatory responses triggered by a thromboembolic model of ischemic stroke and (ii) we examine the efficacy of two clinically tested anti-inflammatory drugs: Minocycline or anti-CD49d antibodies (tested in stroke patients as Natalizumab) administered early (1  h) or late (48 h) after stroke onset. Radiological (lesion volume) and neurological (grip test) outcomes were evalu...
Source: Translational Stroke Research - September 13, 2019 Category: Neurology Source Type: research

Natalizumab Versus Placebo in Patients with Acute Ischemic Stroke (AIS): Results from ACTION, a Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase 2 Clinical Trial (S7.005)
CONCLUSIONS: A single dose of natalizumab administered up to 9 hours after stroke onset did not reduce focal infarct volume growth, but natalizumab appeared to be associated with important functional outcome improvements sustained over 90 days. Further natalizumab studies for AIS are warranted. Support: Biogen.Disclosure: Dr. Elkins holds stock and/or stock options in Biogen, which sponsored research in which Dr. Elkins was involved as a researcher. Dr. Elkind has received personal compensation in and editorial capacity for serving as an Associate Editor of the journal Neurology. Dr. Veltkamp has received research support ...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Elkins, J., Elkind, M., Veltkamp, R., Montaner, J., Johnston, S., Singhal, A., Becker, K., Lansberg, M., Chang, I., Tang, W., Gheuens, S., Mehta, L. Tags: Stroke Clinical Trials Source Type: research

Natalizumab: a new therapy for acute ischemic stroke?
This article reviews the main experimental studies on the blockage of CD49d and identifies the potential underlying causes for their inconclusive results. Despite these divergences and the difficulties in translation of experimental studies, a phase II clinical trial has recently been conducted to evaluate the efficacy of Natalizumab in stroke patients (ACTION trial). Preliminary results of the trial are also discussed here, together with a general overview of the emerged importance of the neuroprotective strategies based on the mitigation of post-stroke neuroinflammation. Expert commentary: Despite Natalizumab showing pos...
Source: Expert Review of Neurotherapeutics - August 2, 2016 Category: Neurology Tags: Expert Rev Neurother Source Type: research

Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Publication date: March 2017 Source:The Lancet Neurology, Volume 16, Issue 3 Author(s): Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind Background In animal models of acute ischaemic stroke, blocking of the leukocyte-endothelium adhesion by antagonism of α4 integrin reduces infarct volumes and improves outcomes. We assessed the effect of one dose of natalizumab, an antibody against the leukocyte adhesion molecule α4 integrin, in patients with acute ischaemic st...
Source: The Lancet Neurology - February 15, 2017 Category: Neurology Source Type: research

Neuroprotection in acute stroke: targeting excitotoxicity, oxidative and nitrosative stress, and inflammation
Publication date: Available online 11 May 2016 Source:The Lancet Neurology Author(s): Ángel Chamorro, Ulrich Dirnagl, Xabier Urra, Anna M Planas Treatments for acute ischaemic stroke continue to evolve after the superior value of endovascular thrombectomy was confirmed over systemic thrombolysis. Unfortunately, numerous neuroprotective drugs have failed to show benefit in the treatment of acute ischaemic stroke, making the search for new treatments imperative. Increased awareness of the relevance of rigorous preclinical testing, and appropriate selection of study participants, might overcome the barriers to progress...
Source: The Lancet Neurology - May 11, 2016 Category: Neurology Source Type: research

Could MS Drug Have a Role in Acute Stroke?Could MS Drug Have a Role in Acute Stroke?
A new study looking at natalizumab to treat stroke showed no effect on the primary endpoint of infarct volume growth, but there was a hint of some clinical benefit. Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - March 7, 2016 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news

Clinical Trials of Immunomodulation in Ischemic Stroke
Abstract Inflammatory mechanisms are currently considered as a prime target for stroke therapy. There is evidence from animal studies that immune signals and mediators can have both detrimental and beneficial effects in particular stages of the disease process. Moreover, several of these mechanisms are turned on with sufficient delay after ischemia onset to make them amenable to therapeutic intervention. Several clinical proof-of concept trials have investigated the efficacy of different immunomodulatory approaches in patients with stroke. Trials targeting the innate immune system have focused on reduction of micr...
Source: Neurotherapeutics - July 12, 2016 Category: Neurology Source Type: research

Topline Results Negative for MS Drug in Acute Stroke Topline Results Negative for MS Drug in Acute Stroke
After natalizumab showed some initial promise in improving clinical outcomes in acute ischemic stroke in a phase 2a study, a phase 2b trial of the drug finds no clinical benefit.Medscape Medical News
Source: Medscape Medical News Headlines - February 9, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Articles Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial
Natalizumab administered up to 9 h after stroke onset did not reduce infarct growth. Treatment-associated benefits on functional outcomes might warrant further investigation.
Source: Lancet Neurology - February 15, 2017 Category: Neurology Authors: Jacob Elkins, Roland Veltkamp, Joan Montaner, S Claiborne Johnston, Aneesh B Singhal, Kyra Becker, Maarten G Lansberg, Weihua Tang, Ih Chang, Kumar Muralidharan, Sarah Gheuens, Lahar Mehta, Mitchell S V Elkind Tags: Articles Source Type: research

Biogen stops developing Tysabri to treat stroke after failed study
(Reuters) - Biogen Inc said on Wednesday it would stop developing Tysabri to treat acute ischemic stroke patients after the drug failed to meet the main goal of a mid-stage study.
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Biogen stops testing Tysabri to treat stroke after study fails
(Reuters) - Biogen Inc said on Wednesday it would stop developing its multiple sclerosis drug Tysabri to treat patients with acute ischemic stroke after it failed a mid-stage study.
Source: Reuters: Health - February 7, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Observational Program Tysabri 24 Plus: Evaluating Efficacy and Safety of Natalizumab Therapy beyond Two Years (P01.161)
CONCLUSIONS: This interim analysis confirms sustained efficacy of NAT in reducing clinical disease activity with a generally consistent known safety profile. A detailed analysis after completion of the study will be presented and may provide data for the optimization of patient selection, monitoring and risk stratification.Supported by: Biogen Idec.Disclosure: Dr. Maurer has received personal compensation for activities with Biogen Idec, TEVA, Genzyme, Sanofi, Bayer, Merck, Boehringer Ingelheim, and Novartis. Dr. Wiendl has received personal compensation for activities with Bayer, Biogen Idec, Elan Corporation, Medac, Merc...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Maurer, M., Wiendl, H., Heesen, C., Gass, A., Wernsdoefer, C., Wettmarshausen, C., Zingler, V., Kieseier, B. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research

Regulatory systems in bone marrow for hematopoietic stem/progenitor cells mobilization and homing.
Abstract Regulation of hematopoietic stem cell release, migration, and homing from the bone marrow (BM) and of the mobilization pathway involves a complex interaction among adhesion molecules, cytokines, proteolytic enzymes, stromal cells, and hematopoietic cells. The identification of new mechanisms that regulate the trafficking of hematopoietic stem/progenitor cells (HSPCs) cells has important implications, not only for hematopoietic transplantation but also for cell therapies in regenerative medicine for patients with acute myocardial infarction, spinal cord injury, and stroke, among others. This paper reviews ...
Source: Biomed Res - July 16, 2013 Category: Research Authors: Alvarez P, Carrillo E, Vélez C, Hita-Contreras F, Martínez-Amat A, Rodríguez-Serrano F, Boulaiz H, Ortiz R, Melguizo C, Prados J, Aránega A Tags: Biomed Res Int Source Type: research

Development of a Functional Scale for Progressive Multifocal Leukoencephalopathy: The NIH PML Scale (S10.005)
CONCLUSIONS: The NIH-PML scale provides a comprehensive functional assessment of the neurological status of this patient population. A specific clinical scale for PML will be important when evaluating future treatment strategies.Disclosure: Dr. Von Geldern has nothing to disclose. Dr. Cortese has nothing to disclose. Dr. Reich has nothing to disclose. Dr. Nath has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Von Geldern, G., Cortese, I., Ohayon, J., Reich, D., Nath, A. Tags: HIV, PML, and Cerebral Malaria Source Type: research

Treating gerstmann's syndrome with natalizumab
We present video, MRI and pathological evidence of the case of a 30 year old woman who developed Gerstmann's syndrome as a result of a tumefactive multiple sclerosis (MS) lesion affecting the left cerebral hemisphere. Intravenous corticosteroids failed to stop rapid enlargement of the index lesion and occurrence of additional hemispheric lesions leading to clinical deterioration. Brain biopsy confirmed the diagnosis of MS. Strong contrast enhancement of the lesions prompted us to start treatment with natalizumab 300 mg i.v. every four weeks leading to sustained disease remission over a 14 month follow-up period though comp...
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 9, 2014 Category: Neurosurgery Authors: Gnanapavan, S., Zane, J., Kelly, P., Sakthivel, G., Klaus, S. Tags: Abstracts Source Type: research